News of Larotrectinib

Larotrectinib has been recommended as a treatment option for NTRK fusion positive patients by multiple international guidelines, including the National Comprehensive Cancer Network (NCCN) in the United States.

Larotrectinib as a broad-spectrum anti-cancer drug, has achieved significant results and multiple important breakthroughs internationally. Its unique therapeutic effect and broad application prospects enable more patients to benefit from this innovative therapy.